Evolutionary rescue model informs strategies for driving cancer cell populations to extinction
Amjad Dabi1, Joel S Brown2,3, Robert A Gatenby2,3,4
1Department of Genetics, University of North Carolina, Chapel Hill, North Carolina, USA.
Abstract:
Cancers exhibit a remarkable ability to develop resistance to a range of treatments, often resulting in relapse following first-line therapies and significantly worse outcomes for subsequent treatments. While our understanding of the mechanisms and dynamics of the emergence of resistance during cancer therapy continues to advance, questions remain about how to minimize the probability that resistance will evolve, thereby improving long-term patient outcomes. Here, we present an evolutionary simulation model of a clonal population of cells that can acquire resistance mutations to one or more treatments. We leverage this model to examine the efficacy of a two-strike "extinction therapy" protocol, in which two treatments are applied sequentially to first contract the population to a vulnerable state and then push it to extinction, and compare it to a combination therapy protocol. We investigate how factors such as the timing of the switch between the two strikes, the rate of emergence of resistant mutations, the doses of the applied drugs, the presence of cross-resistance, and whether resistance is a binary or a quantitative trait affect the outcome. Our results show that the timing of switching to the second strike has a marked effect on the likelihood of driving the cancer to extinction, and that extinction therapy outperforms combination therapy when cross-resistance is present. We conduct an in silico trial that reveals when and why a second strike will succeed or fail. Finally, we demonstrate that our conclusions hold whether we model resistance as a binary trait or as a quantitative, multi-locus trait.
Insights
Cancer resistance to treatment can be overcome with a sequential "extinction therapy" approach. This strategy, involving two treatment strikes, outperforms combination therapy, especially when cross-resistance is present, improving patient outcomes.
Area of Science:
- Evolutionary biology
- Cancer research
- Mathematical modeling
Background:
- Cancer cells frequently develop resistance to treatments, leading to relapse and poorer prognoses.
- Minimizing treatment resistance is crucial for improving long-term patient survival and therapeutic efficacy.
Purpose of the Study:
- To evaluate the effectiveness of a sequential "extinction therapy" protocol against cancer resistance.
- To compare the extinction therapy protocol with standard combination therapy.
- To identify factors influencing the success of cancer extinction therapy.
Main Methods:
- Development of an evolutionary simulation model for a clonal cancer cell population.
- Modeling the acquisition of resistance mutations to single or multiple treatments.
- Investigating the impact of treatment timing, mutation rates, drug doses, cross-resistance, and resistance type (binary vs. quantitative).
Main Results:
- The timing of switching between sequential treatments significantly impacts the probability of cancer extinction.
- Extinction therapy demonstrates superior efficacy compared to combination therapy, particularly in the presence of cross-resistance.
- An in silico trial elucidated the conditions under which the second treatment strike succeeds or fails.
Conclusions:
- Sequential extinction therapy offers a promising strategy to overcome cancer treatment resistance.
- Optimizing the timing of sequential treatments is critical for maximizing therapeutic success.
- The findings are robust across different models of resistance, including binary and quantitative traits.
Related Concept Videos
Treatment Resistant Cancers
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...


